156 related articles for article (PubMed ID: 10174467)
41. The drug budget silo mentality: the Dutch case.
Koopmanschap MA; Rutten FF
Value Health; 2003; 6 Suppl 1():S46-51. PubMed ID: 12846925
[TBL] [Abstract][Full Text] [Related]
42. Pharmaceutical expenditure in Sweden.
Henriksson F; Hjortsberg C; Rehnberg C
Health Policy; 1999 May; 47(2):125-44. PubMed ID: 10538288
[TBL] [Abstract][Full Text] [Related]
43. To cut costs, risky drug use.
Consum Rep; 2011 Nov; 76(11):9. PubMed ID: 22022754
[No Abstract] [Full Text] [Related]
44. Prescription drug trend begins showing modest slowdown.
Capitation Rates Data; 2002 Jul; 7(7):76-80. PubMed ID: 12164063
[No Abstract] [Full Text] [Related]
45. Pharmaceuticals in Medicare reform.
McKercher PL
Clin Ther; 1997; 19(6):1426-32; discussion 1424-5. PubMed ID: 9444450
[TBL] [Abstract][Full Text] [Related]
46. Home-based care a key issue for senior citizens.
Dolsen R
Mich Med; 1994 Jun; 93(6):37-9. PubMed ID: 8057965
[No Abstract] [Full Text] [Related]
47. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients.
Freemantle N; Bloor K
BMJ; 1996 Jun; 312(7044):1469-71. PubMed ID: 8664631
[TBL] [Abstract][Full Text] [Related]
48. Nondialysis (home) medication utilization and cost in diabetic and nondiabetic hemodialysis patients.
Manley HJ; Cannella CA
Nephrol News Issues; 2005 Jan; 19(2):27-8, 33-4, 36-8. PubMed ID: 15717572
[TBL] [Abstract][Full Text] [Related]
49. Reference pricing for drugs: is it compatible with U.S. health care?
Kanavos P; Reinhardt U
Health Aff (Millwood); 2003; 22(3):16-30. PubMed ID: 12757268
[TBL] [Abstract][Full Text] [Related]
50. Prescription drugs and health care reform.
Gibaldi M
Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
[No Abstract] [Full Text] [Related]
51. Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals?
Granlund D
Soc Sci Med; 2009 Dec; 69(11):1643-50. PubMed ID: 19815322
[TBL] [Abstract][Full Text] [Related]
52. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
Ioannides-Demos LL; Ibrahim JE; McNeil JJ
Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
[TBL] [Abstract][Full Text] [Related]
53. Generic medicines. Reducing cost at the expense of quality?
Walker R
Pharmacoeconomics; 1995 May; 7(5):375-7. PubMed ID: 10155324
[No Abstract] [Full Text] [Related]
54. [Potential impact of measures to minimise costs of pharmaceutical provision in the province of Toledo].
Criado-Alvarez JJ; RodrÃguez Caravaca G; Gonseth J; Romo Barrientos C
Aten Primaria; 2004 Feb; 33(3):126-30. PubMed ID: 14987495
[TBL] [Abstract][Full Text] [Related]
55. Strategies to achieve fairer prices for generic and biosimilar medicines.
Ferrario A; Dedet G; Humbert T; Vogler S; Suleman F; Pedersen HB
BMJ; 2020 Jan; 368():l5444. PubMed ID: 31932323
[No Abstract] [Full Text] [Related]
56. Will lower drug prices jeopardize drug research? A policy fact sheet.
Light DW; Lexchin J
Am J Bioeth; 2004; 4(1):W1-4. PubMed ID: 15035915
[No Abstract] [Full Text] [Related]
57. Drug pricing in AFP--how much does a drug cost?
Siwek J
Am Fam Physician; 2010 Jan; 81(2):125. PubMed ID: 20082507
[No Abstract] [Full Text] [Related]
58. Financial consequences of drug benefit plans.
Motheral B; Sheth J
JAMA; 2003 Jan 22-29; 289(4):423-4; author reply 424. PubMed ID: 12533119
[No Abstract] [Full Text] [Related]
59. Financial consequences of drug benefit plans.
Hsu J; Reed M
JAMA; 2003 Jan 22-29; 289(4):423; author reply 424. PubMed ID: 12533118
[No Abstract] [Full Text] [Related]
60. Financial consequences of drug benefit plans.
Clark BE; Garis RI
JAMA; 2003 Jan 22-29; 289(4):423; author reply 424. PubMed ID: 12533117
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
